Gaorui Yaoye (Beijing) Technologies Co Ltd

Primary objective: To determine the maximum tolerated dose (MTD) or phase II recommended dose (RP2D) and safety of BGC0222 for injection in patients with advanced solid tumors who have failed standard treatment (disease progression or intolerance) or lack standard treatment. Secondary objective: To explore the pharmacokinetic (PK) characteristics of BGC0222 for injection monotherapy in patients with advanced solid tumors under single and multiple dosing conditions; to preliminarily evaluate the clinical efficacy of BGC0222 for injection monotherapy in patients with advanced solid tumors (such as colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, breast cancer, non-small/small cell lung cancer, etc.).

The main purpose of the study was to investigate the pharmacokinetic characteristics of a single oral dose of ezetimibe tablets (specification: 10 mg) produced by Beijing Biopharma Co., Ltd. and provided by Gao Ruiyaoye (Beijing) Technology Co., Ltd. on an empty stomach and after meals, and to evaluate the bioequivalence of the two preparations in humans using ezetimibe tablets (trade name: Ezetimibe®, specification: 10 mg) produced by MSD Pharma (Singapore) Pte. Ltd. as the reference preparation. The secondary purpose of the study was to observe the safety of a single oral dose of ezetimibe tablets 10 mg in healthy subjects.

Primary study objective: To evaluate the bioequivalence of Omeprazole Sodium Bicarbonate Capsules (Specifications: Omeprazole 20mg/Sodium Bicarbonate 1100mg) produced by Hebei Renhe Yikang Pharmaceutical Co., Ltd. and Omeprazole Sodium Bicarbonate Capsules (Trade name: ZEGERID®, Specifications: Omeprazole 20mg/Sodium Bicarbonate 1100mg) produced by SALIX PHARMACEUTICALS in healthy subjects under fasting conditions. Secondary study objective: To observe the safety of the test preparation and the reference preparation Omeprazole Sodium Bicarbonate Capsules in healthy subjects.